Association of Non-Invasive Positive Pressure Ventilation with Short-Term Clinical Outcomes in Patients Hospitalized for Acute Decompensated Heart Failure

Midori Yukino 1, Yuji Nagatomo 1,*, Ayumi Goda 2, Takashi Kohno 2, Makoto Takei 3, Yosuke Nishihata 4, Mike Saji 5, Yuichi Toyosaki 6, Shintaro Nakano 6, Yukinori Ikegami 1,*, Yasuyuki Shiraishi 8,*, Shun Kohsaka 8,*, Takeshi Adachi 1 and Tsutomu Yoshikawa 5

1 Department of Cardiology, National Defense Medical College, Tokorozawa 359-8513, Japan; doc33079@ndmc.ac.jp (M.Y.); con467@ndmc.ac.jp (Y.I.); tadachibu@gmail.com (T.A.)
2 Department of Cardiovascular Medicine, Kyorin University School of Medicine, Tokyo 181-8611, Japan; ayumix34@yahoo.co.jp (A.G.); kohno-ta@ks.kyorin-u.ac.jp (T.K.)
3 Department of Cardiology, Saiseikai Central Hospital, Tokyo 108-0073, Japan; makoto_tk@hotmail.com
4 Department of Cardiology, St. Luke’s International Hospital, Tokyo 104-8560, Japan; hatasuke@lue.ac.jp
5 Department of Cardiology, Sakakibara Heart Institute, Tokyo 183-0003, Japan; mikesaji8@gmail.com (M.S.); tyoshi@shli.heart.or.jp (T.Y.)
6 Department of Cardiology, Saitama University International Medical Center, Hidaka 350-1298, Japan; toyoyuki6465@yahoo.co.jp (Y.T.); snakano@saitama-med.ac.jp (S.N.)
7 Department of Cardiology, National Hospital Organization, Tokyo Medical Center, Tokyo 152-8902, Japan
8 Department of Cardiology, Kyorin University Faculty of Medicine, Tokyo 160-8832, Japan; white_cascade_libra@yahoo.co.jp (Y.S.); sk@keio.jp (S.K.)
* Correspondence: con401@ndmc.ac.jp; Tel.: +81-4-2995-1597

Abstract: The real-world evidence has been sparse on the impact of non-invasive positive pressure ventilation (NPPV) on the outcomes in acute decompensated heart failure (ADHF) patients. We aim to explore this issue in the prospective multicenter WET-HF registry. Among 3927 patients (77 (67–84) years, male 60%), the NPPV was used in 775 patients (19.7%). The association of NPPV use with in-hospital outcome and length of hospital stay (LOS) was examined by two methods, propensity score (PS) matching and multivariable analysis with adjustment for PS. In these analyses the NPPV group exhibited a lower endotracheal intubation (ETI) rate and a comparable in-hospital mortality, but longer LOS compared to the non-NPPV group. In the stratified analysis, the NPPV group exhibited a significantly lower ETI rate in patients with ischemic etiology, systolic blood pressure (sBP) > 140 mmHg and the Controlling Nutritional Status (CONUT) score ≤ 3, indicating better nutritional status. On the contrary, NPPV use was associated with longer LOS in patients with non-ischemic etiology, sBP < 100 mmHg and CONUT score > 3. In conclusion, NPPV use was associated with a lower incidence of ETI. Particularly, patients with ischemic etiology, high sBP, and better nutritional status might benefit from NPPV use.

Keywords: NPPV; acute decompensated heart failure; ischemic heart disease; intensive care; endotracheal intubation; length of hospital stay

1. Introduction

Heart failure (HF) is a major social problem that has been increasing in prevalence worldwide due to a rapidly aging society [1]. The current pathophysiologic understanding of acute decompensated HF (ADHF) is incomplete. Due to the lack of adequately conducted trials to address the unmet need for evidence therapy in ADHF, the guideline recommendations for the management of ADHF are based only on algorithms provided by expert consensus guided by blood pressure and/or clinical signs of congestion or hypoperfusion [2]. Non-invasive positive pressure ventilation (NPPV) has been used to treat
acute exacerbations of chronic respiratory diseases instead of traditional endotracheal intubation (ETI) since 1990 [3]. Over the past two decades, NPPV has been increasingly used in patients with acute cardiogenic pulmonary edema (ACPE) [4]. NPPV improves oxygenation, decreases breathing effort [4], and reduces left ventricular afterload [4] and both right and left ventricular preload [5] in patients with ACPE. Prompt improvement in patient-reported dyspnea, acidosis, hypercapnia, and tachycardia has been consistently reported after NPPV use [6].

The small randomized control trials (RCTs) exploring the impact of NPPV using continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP) on the outcomes have been conducted by different research groups [6–9]. In previously conducted RCTs, several significant issues have been indicated, such as a small number of participants in most studies, lack of blinding and possible publication biases. Even the 3CPO trial [6], one of the largest RCTs, failed to demonstrate the beneficial effect of NPPV on short-term mortality. In that study, significant overlap of treatment arms (standard oxygen therapy, CPAP, and NPPV) biased the findings of the outcome, which suggests the difficulty of appropriate randomization in an urgent care setting. Furthermore, the recruitment of patients included in these RCTs was highly selective and the study populations in most of those studies were relatively younger compared to the patients with acute decompensated heart failure (ADHF) in recent years [10,11]. Thus, it remains uncertain whether the findings in these trials can be applicable for the contemporary ADHF population in a real-world setting.

Regarding the impact of NPPV on clinical outcomes, recent meta-analysis [10] demonstrated that NPPV might reduce the need for ETI and in-hospital mortality, although the findings of RCTs were not consistent regarding its impact on mortality [6–9]. However, meta-analysis potentially includes uncontrolled biases due to the lack of description of standard procedures (diuretics, vasodilators, and catecholamines) and the differences in study protocols (intubation criteria, etc.). Further, previous reports including meta-analysis did not fully identify which patient groups would benefit most from NPPV, although one small RCT has shown the beneficial effect of NPPV in patients with acute myocardial infarction-associated pulmonary edema that is not complicated by shock [12]. Hence, we aimed to examine the impact of NPPV on short-term clinical outcomes and to further explore the patient groups who would benefit from NPPV use in the multicenter West Tokyo Heart Failure (WET-HF) registry.

2. Materials and Methods

2.1. Study Design

We analyzed data from 4000 ADHF patients registered in the WET-HF registry from 2006 to 2017. The WET-HF registry is a multicenter prospective cohort registry enrolling all patients hospitalized for ADHF according to the Framingham criteria [13]. In this registry, patients with acute coronary syndrome or isolated right-sided HF were excluded. The clinical diagnosis of ADHF was made by individual cardiologists at each institution. The eight study centers were located in Tokyo, Japan, and included four university hospitals (Keio University, Kyorin University, Saitama Medical University, and National Defense Medical College) and four tertiary referral hospitals (Sakakibara Heart Institute, St. Luke’s International Hospital, Saiseikai Central Hospital, and National Hospital Organization Tokyo Medical Center) [14–16].

Baseline data and outcomes for the WET-HF registry were collected by dedicated clinical research coordinators from medical records and interviews with treating physicians to obtain a robust assessment of the care and patient outcomes. Data regarding NPPV use and ETI were also prospectively collected. Data were entered into an electronic data-capturing system with a robust data query engine and system validations for data quality. Outliers in continuous variables or unexpected values in the categorical variables were selected based on established criteria, and the originating institution was notified to verify the values. The quality of reporting was also verified by the principal investigators (Y.S. and
S.K.) at least once a year, and periodic queries were conducted to ensure quality. Exclusive on-site auditing by the investigators (Y.S. and S.K.) ensured proper registration of each patient. Before the launch of the WET-HF registry, information regarding the objective of the present study, its social significance, and an abstract were provided for clinical trial registration with the University Hospital Medical Information Network (UMIN000001171).

The study protocol was approved by the institutional review boards at each hospital, and the study was conducted in accordance with the principles of the Declaration of Helsinki. Written and/or oral informed consent was obtained from each subject before registration.

Figure 1 shows the flowchart of the present study. Within the cohort, we excluded 73 patients who lacked information regarding NPPV use during the index admission. The remaining 3927 patients (77 (67–84) years, 60% men) were included in the analysis (pre-matched cohort). We categorized them into two groups: patients who received NPPV and those who did not receive NPPV. Additionally, the propensity score was calculated using variables such as age, sex, year of admission, etiology, comorbidities, New York Heart Association (NYHA) functional class, vital signs, symptoms, laboratory data, and pre-admission medication. One-to-one nearest-neighbor propensity matching was conducted between patients from the NPPV group and those from the non-NPPV group, which resulted in 433 pairs available for analysis as the post-matched cohort.

Figure 1. Flowchart of the study. Altogether, 4000 ADHF patients enrolled in WET-HF registry were divided into 2 groups, namely patients who received NPPV and those who did not receive NPPV in the pre-matched cohort. After propensity matching, 433 pairs were available as the post-matched cohort. ADHF: acute decompensated heart failure, WET-HF: West Tokyo Heart Failure, NPPV: non-invasive positive pressure ventilation.
2.2. Endpoint

In the WET-HF registry, information regarding ETI during the index admission was prospectively collected. A follow-up survey using medical charts or telephone reviews was performed, and patients who were lost to follow-up were censored at the date of last contact. Information regarding specific outcomes was obtained from the participating cardiologists and investigators. This information included all-cause mortality, readmission for ADHF, and a composite of all-cause mortality and readmission for ADHF.

2.3. Statistical Analysis

Continuous variables were expressed as mean ± standard deviation for normally distributed data and as median (interquartile range) for data with non-normal distribution. Between-group differences were assessed with an unpaired t-test or the Mann–Whitney U test for the unpaired data, while the chi-squared test was used for the comparison of discrete variables. Kaplan–Meier survival curves were constructed for each group, and differences between the groups were analyzed using the log-rank test.

The propensity score was developed using the clinical variables listed in Table 1. The variables were selected a priori for their potential to be strongly associated with NPPV use. For the multivariable analysis, age, sex, left ventricular ejection fraction (LVEF) and the variables that showed an association with NPPV use in the univariate analysis with p value < 0.1 were employed. The propensity score was then derived using a generalized logistic model to predict the probability of receiving NPPV. The logit of this score was utilized with a caliper of 0.2 to obtain the propensity score for the matching process. Patients from the NPPV and non-NPPV groups were matched using propensity score methods. Greedy nearest-neighbor matching was performed sequentially in a 1:1 fashion without replacement. We calculated the standardized differences to assess bias between the groups. The balance on potential baseline confounders was evaluated using standardized differences, with an importance threshold set at 0.10 a priori.

Table 1. Univariable and multivariable logistic regression for non-invasive positive pressure ventilation Use.

| Variable                  | Univariable | Multivariable |
|---------------------------|-------------|---------------|
|                           | Odds Ratio  | 95% CI        | p Value | Odds Ratio  | 95% CI        | p Value |
| Age                       | 1.006       | 1.000–1.012   | 0.050   | 0.998       | 0.988–1.008   | 0.74    |
| Sex (female)              | 1.097       | 0.935–1.287   | 0.25    | 1.045       | 0.819–1.334   | 0.72    |
| Admission year 2006–2009  | 1 (ref)     | -             | -       | 1 (ref)     | -             | -       |
| 2010–2013                 | 5.726       | 3.630–3.033   | <0.001  | 3.660       | 1.962–6.829   | <0.001  |
| 2014–2017                 | 7.368       | 4.704–11.542  | <0.001  | 6.389       | 3.466–11.76   | <0.001  |
| Etiology ICM              | 0.369       | 0.275–0.494   | <0.001  | 0.461       | 0.300–0.707   | <0.001  |
| DCM                       | 0.598       | 0.486–0.735   | <0.001  | 0.866       | 0.634–1.183   | 0.37    |
| VHD                       | 0.695       | 0.581–0.833   | <0.001  | 0.898       | 0.584–0.950   | 0.45    |
| Prior ADHF admission      | 0.592       | 0.504–0.696   | <0.001  | 0.745       | 0.584–0.950   | 0.18    |
| Atrial fibrillation       | 1.684       | 1.139–2.488   | 0.006   | 1.573       | 0.869–2.847   | 0.14    |
| Home oxygen therapy       | 2.484       | 1.735–3.555   | <0.001  | 1.704       | 0.842–3.449   | 0.14    |
| Dialysis                  | 1.016       | 1.014–1.018   | <0.001  | 1.012       | 1.009–1.016   | <0.001  |
| sBP                       | 1.014       | 1.011–1.016   | <0.001  | 1.009       | 1.005–1.013   | <0.001  |
| SpO₂                      | 0.911       | 0.899–0.923   | <0.001  | 0.914       | 0.898–0.931   | <0.001  |
### Table 1. Cont.

|                              | Univariable |               | p Value | Multivariable |               | p Value |
|------------------------------|-------------|---------------|---------|---------------|---------------|---------|
|                              | Odds Ratio  | 95% CI        |         | Odds Ratio    | 95% CI        |         |
| NYHA (IV/II–III)             | 2.806       | 2.380–3.308   | <0.001  | 2.292         | 1.806–2.909   | <0.001  |
| Cold extremities             | 2.777       | 2.290–3.368   | <0.001  | 2.196         | 1.714–2.814   | <0.001  |
| Rales                        | 2.589       | 2.172–3.087   | <0.001  | 1.554         | 1.221–1.977   | <0.001  |
| BNP/NT-proBNP quartile 1st 1| 1 (ref)     | -             | -       | 1 (ref)       | -             | -       |
|                             | 2nd         | 1.329         | 1.040–1.700 | 0.023     | 1.215         | 0.864–1.708 | 0.26    |
|                             | 3rd         | 1.495         | 1.174–1.904 | 0.001     | 1.175         | 0.789–1.582 | 0.53    |
|                             | 4th         | 2.128         | 1.686–2.686 | <0.001    | 1.191         | 0.822–1.725 | 0.35    |
| CRP                          | 13.421      | 6.292–28.703  | 0.075   | 1.075         | 1.042–1.109   | <0.001  |
| eGFR                         | 0.334       | 0.154–0.713   | 0.005   | 0.999         | 0.993–1.004   | 0.63    |
| LVEF                         | 0.821       | 0.534–1.263   | 0.37    | 0.997         | 0.993–1.007   | 0.58    |
| Prehospital: β-blocker       | 0.751       | 0.639–0.882   | <0.001  | 1.12          | 0.87–1.43     | 0.80    |
| Prehospital: RASi            | 1.220       | 1.029–1.447   | 0.021   | 1.387         | 1.100–1.749   | 0.006   |
| Prehospital: MRA             | 0.556       | 0.433–0.714   | <0.001  | 0.764         | 0.530–1.099   | 0.14    |
| Prehospital: loop diuretics  | 0.632       | 0.537–0.743   | <0.001  | 0.914         | 0.709–1.179   | 0.49    |

CI, confidence interval; ref, reference; ICM, ischemic cardiomyopathy; DCM, dilated cardiomyopathy; VHD, valvular heart disease; ADHF, acute decompensated heart failure; sBP, systolic blood pressure; SpO2, oxygen saturation; NYHA, New York Heart Association; BNP, B-type natriuretic peptide; NT-pro BNP, N-terminal pro B-type natriuretic peptide; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; RASi, renin-angiotensin system inhibitor; MRA, mineralocorticoid receptor antagonist.

Additional analysis was conducted in order to further confirm the association of NPPV use with ETI, in-hospital mortality and length of hospital stay (LOS). Multivariable logistic regression analysis was conducted for each endpoint with adjustment for calculated propensity score in the pre-matched cohort. Multiple regression analysis was conducted to see the association of NPPV use with LOS with adjustment for calculated propensity score in the pre-matched cohort.

We performed a stratified analysis to determine the patient population that would benefit from the use of NPPV. Older age, hypotension, malnutrition [17], and history of ADHF hospitalization [18] are risk factors for adverse outcome in patients with HF. Thus, in addition to basic information such as gender, BMI, and LVEF, the patients were stratified by the factors potentially affecting the effect of NPPV use such as age, sBP, nutritional status and history of ADHF hospitalization. We used the Controlling Nutritional Status (CONUT) score to assess nutritional status. This is a screening tool for the nutritional status of hospitalized patients [19], which is calculated from serum albumin, total cholesterol, and lymphocyte count. These were measured during the index hospitalization in the present study. Interactions between the subgroups were tested and when p value was <0.1, for each stratified group logistic regression analysis was conducted for each endpoint with adjustment for propensity score. Similarly, when p value for interaction was <0.1, multiple regression analysis was conducted to see the association of NPPV use with LOS with adjustment for propensity score.

Statistical significance was set at p < 0.05. All statistical analyses were performed using JMP 14.2.0 (SAS Institute, Cary, NC, USA).

### 3. Results

#### 3.1. Baseline Characteristics

In the pre-matched cohort, 775 (19.7%) patients received NPPV. Baseline characteristics of the NPPV and non-NPPV groups in the pre-matched cohort are presented in Supplement and Table S1.
3.2. Factors Associated with NPPV Use

Multivariable logistic regression analysis was conducted to identify the predictors of NPPV use (Table 1). Admission in the third admission period (2014–2017), ischemic etiology, higher systolic blood pressure (sBP), and parameters representing severe ADHF such as lower oxygen saturation (SpO$_2$), NYHA class IV, and higher B-type natriuretic peptide (BNP)/N-terminal pro B-type natriuretic peptide (NT-pro BNP) were significantly associated with NPPV use. Using these results, the propensity score was calculated and one-to-one nearest-neighbor propensity matching was conducted ($n = 433$ in each group) to adjust for confounding factors such as severity of HF and in-hospital treatment between the groups (Figure 1).

3.3. Findings in the Post-Matched Cohort

In the post-matched cohort, no significant differences were observed in the majority of the baseline characteristics between the NPPV and non-NPPV groups, and the standardized differences were mostly within 0.1 (Table 2). The NPPV group exhibited a lower ETI rate compared to the non-NPPV group (Figure 2A) and comparable in-hospital mortality (Figure 2B) during admission, but LOS was longer in the NPPV group (Figure 2C), as observed in the pre-matched cohort. Since there was a difference in in-hospital treatment between NPPV and non-NPPV groups, multiple regression analysis was conducted. NPPV use was not associated with longer LOS after adjustment of the other in-hospital treatment ($\beta = 0.71$, standard error of the mean [SEM] 0.73, t-value 0.98, $p = 0.33$)

Table 2. Baseline characteristics according to non-invasive positive pressure ventilation use in the post-matched cohort.

|                         | Non-NPPV  | NPPV     | $p$ Value | SDM |
|-------------------------|-----------|----------|-----------|-----|
|                         | ($n = 433$) | ($n = 433$) |           |     |
| Year                    |           |          |           |     |
| 2006–2009 (%)           | 20 (5)    | 15 (3)   | 0.32      | 0.01|
| 2010–2013 (%)           | 142 (33)  | 127 (29) | 0.01      |     |
| 2014–2017 (%)           | 271 (63)  | 291 (67) | 0.01      |     |
| Age (years)             | 77 (67–84)| 78 (69–84)| 0.40      | 0.06|
| Female (%)              | 183 (42)  | 172 (40) | 0.45      | 0.04|
| BMI                     | 23.0 (20.5–25.9) | 23.1 (20.3–26.0) | 0.74 | 0.03|
| Etiology                |           |          |           | 0.97|
| DCM (%)                 | 44 (10)   | 41 (9)   | 0.02      |     |
| ICM (%)                 | 157 (36)  | 156 (36) | 0.01      |     |
| VHD (%)                 | 122 (28)  | 121 (28) | 0.01      |     |
| HFr/mr/pEF              |           |          |           | 0.82|
| HFrEF (%)               | 169 (39)  | 175 (40) | 0.02      |     |
| HFrmrEF (%)             | 85 (20)   | 88 (20)  | 0.02      |     |
| HFP EF (%)              | 179 (41)  | 170 (39) | 0.04      |     |
| Prior ADHF admission (%)| 116 (27)  | 118 (27) | 0.88      | 0.01|
| Atrial Fibrillation (%) | 179 (41)  | 186 (43) | 0.63      | 0.03|
| Hypertension (%)        | 303 (70)  | 313 (72) | 0.45      | 0.05|
|                | Post-Matched Cohort | Non-NPPV (n = 433) | NPPV (n = 433) | p Value | SDM |
|----------------|---------------------|--------------------|---------------|---------|-----|
| Dyslipidemia (%) | 157 (36)            | 196 (45)           | 0.008         | 0.18    |
| DM (%)          | 152 (35)            | 161 (37)           | 0.52          | 0.04    |
| Smoking (%)     | 190 (44)            | 190 (44)           | 1             | 0       |
| Dialysis (%)    | 17 (4)              | 16 (4)             | 0.86          | 0.01    |
| COPD (%)        | 31 (7)              | 17 (4)             | 0.037         | 0.14    |
| Stroke/TIA (%)  | 63 (15)             | 69 (16)            | 0.58          | 0.01    |
| Home oxygen therapy (%) | 22 (5) | 20 (5)             | 0.75          | 0.02    |
| Pacemaker (%)   | 28 (6)              | 27 (6)             | 0.89          | 0.01    |
| ICD (%)         | 11 (3)              | 13 (3)             | 0.68          | 0.03    |
| CRT (%)         | 3 (1)               | 4 (1)              | 0.70          | 0.03    |

### Clinical Presentation at Admission

|                | Non-NPPV (n = 433) | NPPV (n = 433) | p Value |
|----------------|--------------------|---------------|---------|
| NYHA II/III/IV |                    |               | 0.37    |
| II (%)         | 47 (11)            | 60 (14)       | 0.09    |
| III (%)        | 105 (24)           | 107 (25)      | 0.01    |
| IV (%)         | 271 (65)           | 266 (61)      | 0.07    |
| sBP (mmHg)     | 147 (124–172)      | 147 (124–174) | 0.93    | 0     |
| Heart rate (bpm) | 98 (78–118)      | 100 (81–120)  | 0.12    | 0.07  |
| SpO₂ (%)       | 95 (90–97)         | 94 (89–97)    | 0.39    | 0.002 |
| PND (%)        | 193 (45)           | 222 (52)      | 0.029   | 0.15  |
| Orthopnea (%)  | 252 (59)           | 272 (66)      | 0.056   | 0.13  |
| Rales (%)      | 305 (70)           | 297 (69)      | 0.55    | 0.04  |
| Sound III (%)  | 194 (45)           | 212 (50)      | 0.23    | 0.08  |
| JVD (%)        | 217 (52)           | 213 (52)      | 0.91    | 0.01  |
| Edema (%)      | 287 (66)           | 271 (63)      | 0.32    | 0.07  |
| Cold extremities (%) | 150 (35) | 145 (33)      | 0.72    | 0.02  |

### Laboratory Data

|                | Non-NPPV (n = 433) | NPPV (n = 433) | p Value |
|----------------|--------------------|---------------|---------|
| BNP/NT-pBNP quartile |                  |               | 0.92    |
| 1st            | 78 (18)            | 85 (20)       | 0.04    |
| 2nd            | 104 (24)           | 104 (24)      | 0.001   |
| 3rd            | 123 (28)           | 123 (28)      | 0.01    |
| 4th            | 128 (30)           | 121 (28)      | 0.04    |
| BNP (pg/mL)    | 889 (447–1419)     | 871 (432–1575) | 0.97    | 0.08  |
| NT-proBNP (pg/mL) | 4884 (2577–10,017) | 4485 (2356–9239) | 0.70    | 0.09  |
| Hemoglobin (g/dL) | 12.0 (10.4–13.8)  | 11.9 (10.5–13.7) | 0.54    | 0.07  |
| BUN (mg/dL)    | 22.6 (17.8–32.7)   | 22.0 (16.9–33.8) | 0.93    | 0.04  |
| eGFR (mL/min/1.73 m²) | 46.5 (32.9–61.0) | 48.6 (30.4–63.0) | 0.57    | 0.05  |
| UA (mg/dL)     | 6.7 (5.6–8.2)      | 6.4 (5.2–7.9)  | 0.043   | 0.14  |
| Na (mEq/L)     | 140 (137–142)      | 140 (137–142)  | 0.55    | 0.1   |
| CRP (mg/dL)    | 0.7 (0.2–2.4)      | 0.6 (0.2–2.5)  | 0.58    | 0.03  |
Table 2. Cont.

| Post-Matched Cohort | Non-NPPV (n = 433) | NPPV (n = 433) | p Value | SDM |
|---------------------|--------------------|----------------|---------|-----|
| **Echocardiography**|                    |                |         |     |
| LVDd (mm)           | 52 (45–59)         | 52 (46–58)     | 0.97    | 0.003 |
| LVEF (%)            | 45 (32–57)         | 44 (31–58)     | 0.87    | 0.01  |
| LAD (mm)            | 43 (38–49)         | 43 (38–48)     | 0.36    | 0.04  |
| E/e′                | 18.3 (13.2–27.5)   | 19.2 (13.9–26.6)| 0.47   | 0.08  |
| TRPG (mmHg)         | 29 (22–37)         | 29 (23–38)     | 0.45    | 0.03  |
| **Pre-hospital treatment**|                |                |         |     |
| ACE-I/ARB (%)       | 203 (47)           | 208 (48)       | 0.73    | 0.02  |
| β-blocker (%)       | 187 (43)           | 182 (42)       | 0.73    | 0.02  |
| MRA (%)             | 62 (14)            | 48 (11)        | 0.15    | 0.097 |
| Loop diuretic(po.) (%) | 170 (39)          | 171 (39)       | 0.94    | 0.004 |
| Thiazide (%)        | 16 (4)             | 20 (5)         | 0.49    | 0.05  |
| **In-hospital treatment**|                |                |         |     |
| Loop diuretics (iv.) (%) | 313 (72)          | 343 (79)       | 0.017   | 0.03  |
| Nitrates (%)        | 129 (39)           | 197 (46)       | <0.001  | 0.3   |
| Carperitide (%)     | 210 (49)           | 241 (56)       | 0.032   | 0.15  |
| PDE-III (%)         | 14 (3)             | 11 (3)         | 0.55    | 0.04  |
| Catecholamine(%)    | 61 (14)            | 102 (24)       | <0.001  | 0.24  |
| IABP (%)            | 18 (4)             | 12 (3)         | 0.27    | 0.08  |

Categorical values are expressed as percentage, and continuous variables are expressed as median (interquartile range). NPPV, non-invasive positive pressure ventilation; SDM, standardized difference in means; BMI, body mass index; DCM, dilated cardiomyopathy; ICM, ischemic cardiomyopathy; VHD, valvular heart disease; HFREF, HF with reduced ejection fraction; HFrEF, HF with mid-range ejection fraction; HFpEF, HF with preserved ejection fraction; NYHA, New York Heart Association functional class; ADHF, acute decompensated heart failure; DM, diabetes mellitus; COPD, chronic obstructive pulmonary disease; TIA, transient ischemic attacks; ICD, implantable cardioverter defibrillator; CRT, cardiac resynchronization therapy; sBP, systolic blood pressure; SpO2, oxygen saturation; PND, paroxysmal nocturnal dyspnea; JVD, Jugular venous distention; BNP, B-type natriuretic peptide; NT-pro BNP, N-terminal pro B-type natriuretic peptide; BUN, blood urea nitrogen; Cr, serum creatinine; eGFR, estimated glomerular filtration rate; UA, uric acid; Na, serum sodium; T Bil, total bilirubin; CRP, C-reactive protein; LVDd, left ventricular end-diastolic diameter; LVDs, left ventricular end-systolic diameter; LAD, left atrial diameter; TRPG, tricuspid regurgitation pressure gradient; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; MRA, mineralocorticoid antagonist; PDE-III, phosphodiesterase-III inhibitor; IABP, intra-aortic balloon pumping.

Figure 2. In-hospital outcomes in the post-matched cohort. (A) ETI rate, (B) in-hospital mortality, and (C) LOS in the post-matched cohort are depicted. ETI, endotracheal intubation; NPPV, non-invasive positive pressure ventilation; LOS, length of hospital stay.
3.4. Sensitivity Analysis

Additional analysis was conducted in order to further confirm the association of NPPV use with ETI, in-hospital mortality and LOS. Logistic regression analysis was conducted for each endpoint with adjustment for calculated propensity score in the pre-matched cohort. NPPV use was associated with lower incidence of ETI after adjustment for propensity score (Figure 3A). However, NPPV use was not associated with in-hospital death (Figure 3B). Multiple regression analysis revealed that NPPV use was associated with longer LOS (Table 3).

A. ETI Rate - Overall

| Event type | Event rate | Event rate |
|------------|------------|------------|
| NPPV       | 6774       | 3150       |
| Non-NPPV   | 36 (3.3%)  | 108 (11.3%)|

B. In-hospital mortality - Overall

| Event type | Event rate | Event rate |
|------------|------------|------------|
| NPPV       | 46775      | 1113152    |
| Non-NPPV   | 115 (5.9%) | 35 (3.5%)  |

C. ETI Rate - Stratified groups

| Age       | Event type | Event rate | Event rate |
|-----------|------------|------------|------------|
| <75       | NPPV       | 1623       | 3250       |
| ≥75       | Non-NPPV   | 2350       | 1574       |

D. In-hospital mortality - Stratified groups

| BMI       | Event type | Event rate | Event rate |
|-----------|------------|------------|------------|
| Low       | NPPV       | 405        | 2101       |
| Medium    | Non-NPPV   | 1068       | 958        |
| High      | NPPV       | 1524       | 1574       |

Table 3. Multiple regression analysis for LOS with adjustment for propensity score in the pre-matched overall cohort and stratified groups.

| n (NPPV/Non-NPPV) | LOS (NPPV/Non-NPPV) | p for interaction | β | SEM | t-Value | p Value |
|-------------------|---------------------|-------------------|---|-----|--------|---------|
| Overall 775/3152 | 14 (10–27)/14 (10–23) | NA | 1.527 | 0.715 | 2.14 | 0.032 |
| Age <75 | 294/1330 | 15 (10–26)/15 (10–23) | 0.21 | |
| ≥75 | 481/1822 | 18 (11–27)/14 (9–22) | |
| sex Male 450/1901 | 16 (10–26)/14 (10–23) | 0.69 | |
| Female 325/1251 | 19 (11–29)/14 (9–22) | |

Figure 3. In-hospital outcomes with adjustment for propensity score in the pre-matched overall cohort and the stratified groups. (A) ETI rate for overall population, (B) in-hospital mortality for overall population, (C) ETI rate for stratified groups, and (D) in-hospital death for stratified groups are depicted. ETI, endotracheal intubation; NPPV, non-invasive positive pressure ventilation; BMI, body mass index (low BMI: BMI < 18.5, middle BMI: 18.5 ≤ BMI < 25, high BMI: BMI ≥ 25); Hx, history; sBP, systolic blood pressure; LVEF, left ventricular ejection fraction; CONUT, the Controlling Nutritional Status.
Table 3. Multiple regression analysis for LOS with adjustment for propensity score in the pre-matched overall cohort and stratified groups.

|                    | n (NPPV/Non-NPPV) | LOS (NPPV/Non-NPPV) | p for Interaction | β   | SEM  | t-Value | p Value |
|--------------------|-------------------|---------------------|------------------|-----|------|---------|---------|
| Overall            | 775/3152          | 14 (10–27)/14 (10–23) | NA               | 1.527 | 0.715 | 2.14    | 0.032   |
| Stratified groups  |                   |                     |                  |     |      |         |         |
| Age <75            | 294/1330          | 15 (10–26)/15 (10–23) | 0.21             |     |      |         |         |
| ≥75                | 481/1822          | 18 (11–27)/14 (9–22) |                 |     |      |         |         |
| sex Male           | 450/1901          | 16 (10–26)/14 (10–23) | 0.69             |     |      |         |         |
| Female             | 325/1251          | 19 (11–29)/14 (9–22) |                 |     |      |         |         |
| Low                | 82/32             | 16 (9–28)/15 (9–28)  |                 |     |      |         |         |
| BMI Middle         | 388/1714          | 17 (11–27)/14 (10–22) | 0.73             |     |      |         |         |
| High               | 211/648           | 17 (10–26)/14 (9–21) |                 |     |      |         |         |
| Etiology Low       | 302/840           | 17 (10–26)/15 (10–23) | 0.008            | 0.069 | 1.217 | 0.06 | 0.96 |
| Middle             | 473/2312          | 17 (11–27)/14 (9–22) | 0.007            | 2.375 | 0.88  | 2.69 | 0.007 |
| ischemic           |                   |                     |                  |     |      |         |         |
| No                 | 189/992           | 16 (9–26)/14 (10–24) | 0.084            | 1.404 | 1.646 | 0.85 | 0.39 |
| sBP ≥140           | 491/1327          | 16 (10–24)/14 (9–21) | 1.362            | 1.666 | 0.754 | 2.02 | 0.044 |
| sBP <140           | 232/1530          | 19 (12–31)/14 (10–23) | 0.062            | 0.548 | 1.25  | 0.44 | 0.66 |
| sBP <100           | 52/287            | 25 (12–40)/17 (10–31) | 7.077            | 2.338 | 3.03  | 0.003 |         |
| Hx of ADHF admission | 473/1789         | 17 (10–27)/15 (10–24) | 0.50             |     |      |         |         |
| No                 | 583/2128          | 17 (11–27)/14 (9–22) | 1.362            | 1.666 | 0.754 | 2.02 | 0.044 |
| sBP ≥140           | 491/1327          | 16 (10–24)/14 (9–21) | 1.362            | 1.666 | 0.754 | 2.02 | 0.044 |
| sBP <140           | 232/1530          | 19 (12–31)/14 (10–23) | 0.062            | 0.548 | 1.25  | 0.44 | 0.66 |
| sBP <100           | 52/287            | 25 (12–40)/17 (10–31) | 7.077            | 2.338 | 3.03  | 0.003 |         |
| LVEF ≥50           | 287/1322          | 18 (11–27)/13 (9–21) | 0.50             |     |      |         |         |
| Low                | 473/2312          | 17 (11–27)/14 (9–22) | 0.007            | 2.375 | 0.88  | 2.69 | 0.007 |
| Middle             | 179/530           | 14 (9–26)/13 (9–21)  | 0.57             | 0.523 | 0.919 | 0.57 | 0.57 |
| High               | 248/848           | 17 (10–26)/15 (10–23) | 0.044            | 0.404 | 1.306 | 3.1  | 0.002 |

LOS, length of hospital stay; NPPV, non-invasive positive pressure ventilation; SEM, standard error of the mean; BMI, body mass index; ADHF, acute decompensated heart failure; Hx, history; sBP, systolic blood pressure; LVEF, left ventricular ejection fraction; CONUT, the Controlling Nutritional Status.

3.5. Stratified Analysis

The stratified analysis was conducted. For ETI rate, interactions between the subgroups were seen in etiology (ischemic or non-ischemic), sBP, LVEF, and CONUT score (Figure 3C). In ischemic etiology, sBP > 140, LVEF < 50%, and CONUT score < 3 (indicating better nutritional status), the NPPV group exhibited a lower ETI rate (Figure 3C). For in-hospital mortality, only the history of ADHF admission modified the effect of NPPV. But NPPV use was not associated with significant changes in in-hospital mortality, either in patients with previous ADHF admission or those without (Figure 3D). For LOS, interactions between the subgroups were seen in etiology (ischemic or non-ischemic), previous ADHF admission, sBP and CONUT score. In contrast to the findings of ETI rate, the NPPV group was associated with a longer LOS in the following subgroups: non-ischemic etiology, no previous ADHF admission, sBP < 100 mmHg, and poorer nutritional status indicated by CONUT score > 3 (Table 3).

4. Discussion

In the present study, we demonstrated the following main findings: (1) In the post-matched cohort, NPPV use was associated with a lower ETI rate, but there were no differences in in-hospital mortality during admission. NPPV use was associated with slightly longer LOS, but it was not statistically significant after adjustment for in-hospital treatment. (2) Lower ETI rate, no effect in in-hospital mortality and longer LOS in NPPV group were further confirmed by the analysis in the pre-matched cohort with adjustment for propensity score. (3) NPPV use was associated with a lower ETI rate in some subgroups such as patients with ischemic etiology, sBP > 140 mmHg at admission, LVEF < 50%, and better nutritional status indicated by CONUT score ≤ 3. (4) NPPV use was associated with a longer LOS in patients with non-ischemic etiology, no history of ADHF admission, sBP < 100 mmHg, and poorer nutritional status indicated by CONUT score > 3.

These findings suggest that NPPV use might be associated with benefits such as avoidance of ETI. Furthermore, some subgroups such as patients with ischemic etiology might benefit from NPPV but, on the contrary, others might experience disadvantages such as longer LOS along with receiving NPPV. The strength of our study is that we were able to eliminate bias by analysis using propensity score to align patient backgrounds.
Moreover, stratified analysis clearly suggest the subgroups that showed advantages and/or disadvantages along with receiving NPPV in a real-world setting.

4.1. Impact of NPPV Use on ACPE

The clinical use of NPPV has been increasing since the 1980s, and small RCTs have evaluated the efficacy of NPPV in ACPE [6–10,20]. Several studies have shown the benefit of NPPV in terms of reduced ETI rate, but findings regarding the impact of NPPV on in-hospital mortality had been inconsistent [8,9,17,18]. In this context, the recommendations regarding the use of NPPV in ACPE are inconsistent between the European Society of Cardiology guidelines (class IIa) [21] and the American College of Cardiology/American Heart Association guidelines, which do not provide treatment guidance for ACPE [22]. According to a recent meta-analysis of RCTs analyzing the use of NPPV to treat ACPE, NPPV use was associated with reduced in-hospital mortality as well as ETI rate [10].

The results of the present study are in line with the results published to date in terms of reduced ETI. Furthermore, a risk ratio for ETI in the propensity match analysis was 0.515 and an estimated risk ratio calculated from OR in the multivariable regression analysis [23] was 0.480 (Figures 2A and 3A). From these findings the effect sizes in our study were also consistent with the recent meta-analysis (risk ratio 0.49) [10].

The lack of benefit in terms of in-hospital mortality might be due to the lower overall mortality in the present cohort. Although most of the previous studies reported in-hospital mortality exceeding 10% [10,24–26], it was as low as 4% in the present study (Figure 2).

4.2. The Relationship among Ischemic Etiology, Hypertension, and NPPV Use

In the present study, ischemic etiology and higher sBP were associated with NPPV use (Table 2). Hypertension is closely associated with impaired relaxation [27] and stiffness [28] of the left ventricular myocardium. The combination of physiological and/or psychological stress causes vasoconstriction through neurohormonal activation, leading to an increase in the left atrial pressure. This continuum of responses causes further distress, resulting in rapid development of “flash” pulmonary edema [29]. Ischemic etiology [15] and higher aortic stiffness [30,31] are also among the factors related to this pathology.

On the other hand, the stratified analysis revealed that NPPV use might provide benefits, especially for patients with ischemic etiology and sBP > 140 mmHg, in terms of reduced ETI rate. Quick application of NPPV in patients with ADHF might be advantageous for those with rapidly progressing oxygen desaturation caused by the aforementioned mechanism. We propose reduced right and left ventricular preload [32] and LV afterload due to decreased transmural (or transthoracic) pulmonary pressure [33] by positive pressure ventilation as another potential mechanism mediating the benefit of NPPV in these subgroups. A positive association was observed between elevated left ventricular end-diastolic pressure and subendocardial ischemia [34]. In addition, NPPV promptly improves oxygenation, which can ameliorate myocardial ischemia [4].

4.3. The Subgroups Associated with Longer LOS along with Receiving NPPV

In the present study, LOS was longer in the NPPV group even in the post-matched cohort (Figure 2C), although it was not statistically significant after adjustment for other in-hospital treatment. Recent meta-analysis did not show a statistically significant difference in LOS between NPPV and non-NPPV groups [10]. However, the recent finding from the registry showed prolonged LOS in NPPV group even after propensity matching [26]. Collectively, those findings including the present study might suggest the association of NPPV use with longer LOS exclusively in real-world settings. NPPV use was associated with prolonged LOS, especially in females and in patients with age ≥ 75 years, non-ischemic etiology, and poorer nutritional status indicated by CONUT score > 3. Interestingly, in some of the subgroups, one group showed the benefit of NPPV in terms of ETI avoidance, while the other was associated with longer LOS (e.g., age ≥75 vs. <75, non-ischemic vs. ischemic, CONUT score ≤3 vs. >3). Previous studies have reported that older age, female
sex [35], and poorer nutritional status [36] were associated with frailty, which in turn was associated with a high risk for short-term adverse outcomes and longer LOS [37]. These patient groups might be prone to complications or deconditioning during or after NPPV application.

4.4. Limitations

The present study has some limitations. This study was based on observational registry data. Despite covariate adjustment using propensity matching, unmeasured or unknown variables might have influenced the outcomes. Since the deviation of in-hospital treatment remained even after post-matched cohort, it might have influenced our findings. The small number of in-hospital events did not allow us to conduct the multivariable analysis due to the concern for overfitting, especially in the stratified analysis. The decision to use NPPV was made by the attending physician, resulting in selection bias. Information regarding the timing, situation (emergency department, intensive care unit, or general ward), duration of NPPV use, mode of NPPV (CPAP or BIPAP), setting (the pressure at inspiration and expiration), and the brand of NPPV equipment was not collected. Data regarding the details of adverse events related to NPPV use were not collected. Since this study involved only Japanese subjects, our findings might not be applicable to other countries due to factors such as a unique insurance system and long hospital stay. Increased frequency of NPPV use over time might suggest a learning curve effect and the findings need to be interpreted with caution, although the year of admission was adjusted in the propensity matching process.

5. Conclusions

The NPPV group showed comparable in-hospital outcomes with the non-NPPV group within the matched cohort. However, NPPV might prevent ETI in ADHF patients with respiratory distress. Particularly, patients with younger age, coronary artery disease, and better nutritional status might benefit from NPPV use. On the contrary, we need caution when applying NPPV for the patients with features related to frailty such as elderly, female, or poorer nutritional status, since it might lead to longer LOS.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/jcm10215092/s1, Figure S1: In-hospital outcomes in the pre-matched cohort. Figure S2: Short-term survival analysis for 90 days after discharge. Table S1: Baseline characteristics according to non-invasive positive pressure ventilation use in the pre-matched cohort. Table S2: LOS for the patients who received NPPV and those who did not in the stratified subgroups in the post-matched cohort.

Author Contributions: Conceptualization, M.Y. and Y.N. (Yuji Nagatomo); methodology, M.Y. and Y.N. (Yuji Nagatomo); software, M.Y. and Y.N. (Yuji Nagatomo); validation, M.Y. and Y.N. (Yuji Nagatomo); formal analysis, M.Y. and Y.N. (Yuji Nagatomo); investigation, M.Y. and Y.N. (Yuji Nagatomo); resources, M.Y. and Y.N. (Yuji Nagatomo); data curation, M.Y. and Y.N. (Yuji Nagatomo); writing—original draft preparation, M.Y. and Y.N. (Yuji Nagatomo); writing—review and editing, M.Y. and Y.N. (Yuji Nagatomo); visualization, M.Y. and Y.N. (Yuji Nagatomo); supervision, Y.N. (Yuji Nagatomo), A.G., T.K., M.T., Y.N. (Yosuke Nishihata), M.S., Y.T., S.N., Y.I., Y.S., S.K., T.A. and T.Y.; project administration, Y.S. and S.K.; funding acquisition, S.K., T.Y. and Y.N. (Yuji Nagatomo). All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by a Grant-in-Aid for Young Scientists (Japan Society for the Promotion of Science) (Japan Society for the Promotion of Science KAKENHI, 18K15860(Y.S.); a Grant-in-Aid for Scientific Research [#20H03915 (S.K.), #20K08408 (T.K.), #18K08056 (T.Y.), #17K09526 (T.K.), #16KK0186 (S.K.), #16H05215 (S.K.), #23591062 (T.Y.), #26461088 (T.Y.), #16K09469 (Yuji Nagatomo)], a Health Labour Sciences Research Grant [#14528506, (S.K.)], the Japan Agency for Medical Research and Development [201439013C] (S.K) and the Sakakibara Clinical Research Grant for the Promotion of Sciences, 2012–2019 (T.Y). The authors declare no conflict of interest.
Institutional Review Board Statement: The study protocol was approved by the institutional review boards at each site, and research was conducted in accordance with the Declaration of Helsinki. Ethical approval for the study was granted by the institutional review boards of Keio University Hospital (20090176), Kyorin University (605), Saitama Medical University (15-071), Sakakibara Heart Institute (11-021), St. Luke’s International Hospital (17-R074), Saiseikai Central Hospital (28-55), and National Hospital Organization Tokyo Medical Center (R20-172).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data underlying this article cannot be shared publicly to maintain the privacy of individuals that participated in the study. The data will be shared on reasonable request to the corresponding author.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Ponikowski, P.; Anker, S.D.; AlHabib, K.F.; Cowie, M.R.; Force, T.L.; Hu, S.; Jaarsma, T.; Krum, H.; Rastogi, V.; Rohde, L.E.; et al. Heart failure: Preventing disease and death world-wide. ESC Heart Fail. 2014, 1, 4–25. [CrossRef] [PubMed]

2. Antohi, E.-L.; Ambrosy, A.P.; Collins, S.P.; Ahmed, A.; Iliescu, V.A.; Cotter, G.; Pang, P.S.; Butler, J.; Chioncel, O. Therapeutic Advances in the Management of Acute Decompensated Heart Failure. Am. J. Ther. 2019, 26, e222–e233. [CrossRef]

3. Brochard, L.; Isaïey, D.; Piquet, J.; Amaro, P.; Mancebo, J.; Messadi, A.A.; Brun-Buisson, C.; Rauss, A.; Lemaire, F.; Harf, A. Reversal of acute exacerbations of chronic obstructive lung disease by inspiratory assistance with a face mask. N. Engl. J. Med. 1990, 323, 1523–1530. [CrossRef]

4. Lin, M.; Yang, Y.F.; Chiang, H.T.; Chang, M.S.; Chiang, B.N.; Cheitlin, M.D. Reappraisal of continuous positive airway pressure therapy in acute cardiogenic pulmonary edema. Short-term results and long-term follow-up. Chest 1995, 107, 1379–1386. [CrossRef]

5. Chadda, K.; Annane, D.; Hart, N.; Gajdos, P.; Raphaël, J.C.; Lofaso, F. Cardiac and respiratory effects of continuous positive airway pressure and noninvasive ventilation in acute cardiac pulmonary edema. Crit. Care Med. 2002, 30, 2457–2461. [CrossRef]

6. Gray, A.; Goodacre, S.; Newby, D.E.; Masson, M.; Sampson, F.; Nicholl, J. Noninvasive Ventilation in Acute Cardiogenic Pulmonary Edema. N. Engl. J. Med. 2008, 359, 142–151. [CrossRef]

7. Nava, S.; Carbone, G.; DiBattista, N.; Bellone, A.; Biaardi, P.; Cosentini, R.; Marenco, M.; Girofra, F.; Borasi, G.; Gropp, P. Noninvasive ventilation in cardiogenic pulmonary edema: A multicenter randomized trial. Am. J. Respir. Crit. Care Med. 2003, 168, 1432–1437. [CrossRef]

8. Ducros, L.; Logeart, D.; Vicaut, E.; Henry, P.; Plaisance, P.; Collet, J.-P.; Broche, C.; Gueye, P.; Vergne, M.; on behalf of the CPAP collaborative study group; et al. CPAP for acute cardiogenic pulmonary oedema from out-of-hospital to cardiac intensive care unit: A randomised multicentre study. Intensive Care Med. 2011, 37, 1501–1509. [CrossRef]

9. Frontin, P.; Bounes, V.; Houzé-Cerfon, C.H.; Charpentier, S.; Houzé-Cerfon, V.; Ducassé, J.L. Continuous positive airway pressure for cardiogenic pulmonary edema: A randomized study. Am. J. Emerg. Med. 2011, 29, 775–781. [CrossRef]

10. Berbenetz, N.; Wang, Y.; Brown, J.; Godfrey, C.; Ahmad, M.; Vital, F.M.; Lambiase, P.; Banerjee, A.; Bakhai, A.; Chong, M. Non-invasive positive pressure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary oedema. Cochrane Database Syst. Rev. 2019, 4, CD005351. [CrossRef] [PubMed]

11. Shiraishi, Y.; Kohsaka, S.; Sato, N.; Takano, T.; Kitai, T.; Yoshikawa, T.; Matsue, Y. 9-Year Trend in the Management of Acute Heart Failure in Japan: A Report From the National Consortium of Acute Heart Failure Registries. J. Am. Heart Assoc. 2018, 7, e008677. [CrossRef] [PubMed]

12. Takeda, S.; Nejima, J.; Takano, T.; Nakanishi, K.; Takayama, M.; Sakamoto, A.; Ogawa, R. Effect of Nasal Continuous Positive Airway Pressure on Pulmonary Edema Complicating Acute Myocardial Infarction. Jpn. Circ. J. 1998, 62, 553–558. [CrossRef] [PubMed]

13. McKee, P.A.; Castelli, W.P.; McNamara, P.M.; Kannel, W.B. The Natural History of Congestive Heart Failure: The Framingham Study. N. Engl. J. Med. 1971, 285, 1441–1446. [CrossRef]

14. Yagawa, M.; Nagatomo, Y.; Izumi, Y.; Mahara, K.; Tonomine, H.; Shiraishi, Y.; Kohno, T.; Mizuno, A.; Goda, A.; Kohsaka, S.; et al. Effect of Obesity on the Prognostic Impact of Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction. Circ. J. 2017, 81, 966–973. [CrossRef]

15. Komuro, J.; Nagatomo, Y.; Mahara, K.; Isobe, M.; Goda, A.; Sujino, Y.; Mizuno, A.; Shiraishi, Y.; Kohno, T.; Kohsaka, S.; et al. Clinical Scenario Classification for Characterization and Outcome Prediction of Acute Decompensated Heart Failure Under Contemporary Phenotyping. Circ. Rep. 2019, 1, 162–170. [CrossRef]

16. Fukuoka, R.; Kohno, T.; Kohsaka, S.; Shiraishi, Y.; Sawano, M.; Abe, T.; Nagatomo, Y.; Goda, A.; Mizuno, A.; Fukuda, K.; et al. Prediction of sudden cardiac death in Japanese heart failure patients: International validation of the Seattle Proportional Risk Model. Europace 2020, 22, 588–597. [CrossRef] [PubMed]
17. Narumi, T.; Arimoto, T.; Funayama, A.; Kadowaki, S.; Otaki, Y.; Nishiyama, S.; Takahashi, H.; Shishido, T.; Miyashita, T.; Miyamoto, T.; et al. The prognostic importance of objective nutritional indexes in patients with chronic heart failure. J. Cardiol. 2013, 62, 307–313. [CrossRef]

18. Akita, K.; Kohno, T.; Kohsaka, S.; Shiraiishi, Y.; Nagatomo, Y.; Goda, A.; Mizuno, A.; Suzuki, Y.; Fukuoka, K.; Yoshikawa, T.; et al. Prognostic Impact of Previous Hospitalization in Acute Heart Failure Patients. Circ. J. 2019, 83, 1261–1268. [CrossRef]

19. Ignacio de Ulíbarri, J.; González-Madroño, A.; de Villar, N.G.; González, P.; González, B.; Mancha, A.; Rodríguez, F.; Fernández, G. CONUT: A tool for con-trolling nutritional status. First validation in a hospital population. Nutr. Hosp. 2005, 20, 38–45.

20. Nava, S.; Hill, N. Non-invasive ventilation in acute respiratory failure. Lancet 2009, 374, 250–259. [CrossRef]

21. Ponikowski, P.; Voors, A.A.; Anker, S.D.; Bueno, H.; Cleland, J.G.F.; Coats, A.S.J.; Falk, V.; González-Juanatey, J.R.; Harjola, V.P.; Jankowska, E.A.; et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2016, 37, 2129–2200.

22. Yancy, C.W.; Jessup, M.; Bozkurt, B.; Butler, J.; Casey, D.E., Jr.; Drazner, M.H.; Fonarow, G.C.; Geraci, S.A.; Horwich, T.; Januzzi, J.; et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on prac-tice guidelines. Circulation 2013, 128, e240–e327. [CrossRef]

23. Viera, A.J. Odds Ratios and Risk Ratios: What’s the Difference and Why Does It Matter? South. Med. J. 2008, 101, 730–734. [CrossRef] [PubMed]

24. Pirracchio, R.; Rigon, M.R.; Mebazaa, A.; Zannad, F.; Alla, F.; Chevret, S. Continuous Positive Airway Pressure (CPAP) May Not Reduce Short-Term Mortality in Cardiogenic Pulmonary Edema: A Propensity-Based Analysis. J. Card. Fail. 2013, 19, 108–116. [CrossRef]

25. Schnell, D.; Timsit, J.-F.; Darmon, M.; Vesin, A.; Goldgran-Toledano, D.; Dumenil, A.-S.; Garrouste-Orgeas, M.; Adrie, C.; Bouadma, L.; Planquette, B.; et al. Noninvasive mechanical ventilation in acute respiratory failure: Trends in use and outcomes. Intensive Care Med. 2014, 40, 582–591. [CrossRef] [PubMed]

26. Miró, O.; Martínez, G.; Masip, J.; Gil, V.; Martín-Sánchez, F.J.; Llorens, P.; Herrero-Puente, P.; Sánchez, C.; Richard, F.; Lucas-Invernón, J.; et al. Effects on short term outcome of non-invasive venti-lation use in the emergency department to treat patients with acute heart failure: A propensity score-based analysis of the EAHFE Registry. Eur. J. Intern. Med. 2018, 53, 45–51. [CrossRef]

27. Leite-Moreira, A.F.; Correa-Pinto, J. Load as an acute determinant of end-diastolic pressure-volume relation. Am. J. Physiol. Circ. Physiol. 2001, 280, H51–H59. [CrossRef] [PubMed]

28. López, B.; Gonzalez, A.; Varo, N.; Laviades, C.; Querejeta, R.; Diez, J. Biochemical Assessment of Myocardial Fibrosis in Hypertensive Heart Disease. Hypertension 2001, 38, 1222–1226. [CrossRef] [PubMed]

29. Kumar, R.; Gandhi, S.K.; Little, W.C. Acute heart failure with preserved systolic function. Crit. Care Med. 2008, 36, S52–S56. [CrossRef] [PubMed]

30. Mitchell, G.F.; Hwang, S.-J.; Vasan, R.S.; Larson, M.G.; Levy, D.; Benjamin, E.J.; Pencina, M.J.; Hamburg, N.M.; Vita, J.A. Response to Letters Regarding Article, “Arterial Stiffness and Cardiovascular Events: The Framingham Heart Study”. Circulation 2010, 122, 505–511. [CrossRef]

31. Namba, T.; Masaki, N.; Matsuo, Y.; Sato, A.; Kimura, T.; Horii, Y.; Yasuda, R.; Yada, H.; Kawamura, A.; Takaseet, B.; et al. Arterial Stiffness Is Significantly Associated With Left Ven-tricular Diastolic Dysfunction in Patients with Cardiovascular Disease. Int. Heart J. 2016, 57, 729–735. [CrossRef]

32. Lenique, F.; Habis, M.; Lofaso, F.; Dubois-Randé, J.L.; Harf, A.; Brochard, L. Ventilatory and hemodynamic effects of continuous positive airway pressure in left heart failure. Am. J. Respir. Crit. Care Med. 1997, 155, 500–505. [CrossRef]

33. Wiesen, J.; Ornstein, M.; Tonelli, A.; Menon, V.; Ashton, R.W. State of the evidence: Mechanical ventilation with PEEP in patients with cardiogenic shock. Heart 2013, 99, 1812–1817. [CrossRef] [PubMed]

34. Elhabyan, A.K.; Reyes, B.J.; Hallak, O.; Broce, M.; Rosencrance, J.G.; Lucas, B.D.; Fazal, H. Subendocardial ischemia without coronary artery disease: Is elevated left ventricular end diastolic pressure the culprit? Curr. Med. Res. Opin. 2004, 20, 773–777. [CrossRef]

35. Collard, R.M.; Boter, H.; Schoevers, R.A.; Oude Voshaar, R.C. Prevalence of frailty in community-dwelling older persons: A systematic review. J. Am. Geriatr. Soc. 2012, 60, 1487–1492. [CrossRef] [PubMed]

36. Bos, C.; Benamouzig, R.; Bruhat, A.; Roux, C.; Mahé, S.; Valensi, P.; Gaudichon, C.; Ferrière, F.; Rautureau, J.; Tomé, D. Short-term protein and energy supplementation activates nitrogen kinetics and accretion in poorly nourished elderly subjects. Am. J. Clin. Nutr. 2000, 71, 1129–1137. [CrossRef] [PubMed]

37. Kundi, H.; Wadhera, R.K.; Strom, J.B.; Valsdottir, L.R.; Shen, C.; Kazi, D.S.; Yeh, R.W. Association of Frailty With 30-Day Outcomes for Acute Myocardial Infarction, Heart Failure, and Pneumonia Among Elderly Adults. JAMA Cardiol. 2019, 4, 1084–1091. [CrossRef]